Kodiak Sciences Inc.
KOD
Rang in aandelen
#3111
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Aandeelprijs
$91.51
Marktkapitalisatie
$5.75B
Verandering (1 dag)
6.72%
Verandering (1 jaar)
549.01%
Land
US
Handel Kodiak Sciences Inc. (KOD)
Categorie
Healthcare
Dividendgeschiedenis van Kodiak Sciences Inc. (KOD)
Kodiak Sciences Inc. (aandelsymbool: KOD) heeft in totaal 0 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: 0.00
Dividendrendement (TTM): 0
De som van alle dividenden (aangepast voor aandelensplitsingen) is: 0.00
Dividendrendement (TTM): 0
Dividendbetalingen voor Kodiak Sciences Inc. (KOD) van 2026 tot 2026
Jaarlijkse dividendbetalingen
| Jaar | Dividend (aangepast voor aandelensplitsingen) | Wijzigen |
|---|---|---|
| Niet genoeg gegevens voor de verstrekte datums. | ||
Lijst van alle dividendbetalingen
| Jaar | Dividend | Wijzigen |
|---|---|---|
| Niet genoeg gegevens voor de verstrekte datums. | ||
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
| Bedrijf | Aantal dividendbetalingen | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
